Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
One hundred thirty patients with previously treated advanced breast cancer were treated in a cooperative trial to investigate the effect of mitomycin plus tamoxifen (MT) and to compare its relative value to combination therapy with mitolactol, doxorubicin (ADM), and tamoxifen. An additional 76 patients who had had prior exposure to ADM were randomized to receive MT or MT plus fluoxymesterone. MT versus mitolactol, ADM, and tamoxifen was not significantly different in efficacy; however, there were significant differences in toxicity. This study showed that MT is an effective and acceptable second-line treatment for advanced breast cancer.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003561:Cytarabine; D003630:Daunorubicin; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005474:Fluoxymesterone / Q000008:administration & dosage; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D008936:Mitolactol / Q000008:administration & dosage; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D010976:Platelet Count; D011897:Random Allocation; D013629:Tamoxifen / Q000008:administration & dosage; D013866:Thioguanine
D008937:Mitomycins; D003561:Cytarabine; D013629:Tamoxifen; D016685:Mitomycin; D004317:Doxorubicin; D005474:Fluoxymesterone; D013866:Thioguanine; D008936:Mitolactol; D003630:Daunorubicin